About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main objectives are to improve the diagnosis of immunodeficiencies and autoimmune diseases, addressing also their heterogeneity and mechanisms in close collaboration with the pediatrics, thyroid and systemic disease groups, being internationally recognized in both areas. The group participates in numerous research projects at the Vall d'Hebron Barcelona Hospital Campus that use immunological tests developed for specific projects led by the kidney transplantation, intensive care medicine, internal medicine, allergy and rheumatology groups. During the COVID pandemic the group made contributions in improving the immunogenetic and immunological risk profiles and in the evaluation of the immune response to vaccination and natural infection, collaborating with national and international networks. The group has also generated a biobank of more than 8.000 samples from patients with COVID-19 that have been incorporated into the VHIR biobank.
The group works as a coordinator of the "Focis" Center of Excellence (Federation of Clinical Immunology Societies) of Barcelona.
IP: Pere Soler Palacín Collaborators: Antoni Soriano Arandes, Jorgina Vila Soler, Laura Batlle Masó, Natalia Ana Mendoza Palomar, Maria Espiau Guarner, Aurora Fernandez Polo, Núria Worner Tomasa, Laura Lopez Seguer, Miriam Gonzalez Amores, Susana Melendo Perez, Sonia Rodriguez Tello, Andrea Martín Nalda, Claudia Broto Cortes, Marie Antoinette Frick, Jacques Gabriel Rivière Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00441 Duration: 01/01/2022 - 30/06/2025
IP: Alfredo Guillen Del Castillo Collaborators: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla, Maria Roca Herrera, Janire Perurena Prieto, Irene Sansano Valero Funding agency: Instituto de Salud Carlos III Funding: 75020 Reference: PI22/01804 Duration: 01/01/2023 - 31/12/2025
IP: Mar Guilarte Clavero Collaborators: Manuel Hernández González, Moisés Labrador Horrillo, Anna Sala Cunill, Olga Luengo Sanchez, Paula Galvan Blasco, Ingrid Johana Gil Serrano Funding agency: Instituto de Salud Carlos III Funding: 84700 Reference: PI20/01061 Duration: 01/01/2021 - 30/06/2025
IP: Roger Colobran Oriol Collaborators: Aina Aguiló Cucurull, Andrea Martín Nalda, Laura Batlle Masó Funding agency: Instituto de Salud Carlos III Funding: 159720 Reference: PI20/00761 Duration: 01/01/2021 - 30/06/2025
The paper describes the case of a patient in whom, years after a bone marrow transplant, two immune cell lines corrected the original genetic defect.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
